CA3140231A1 - Compose propylamine heteroaryle 3-aryloxyl-3 a cinq chainons, forme cristalline et utilisation associee - Google Patents
Compose propylamine heteroaryle 3-aryloxyl-3 a cinq chainons, forme cristalline et utilisation associee Download PDFInfo
- Publication number
- CA3140231A1 CA3140231A1 CA3140231A CA3140231A CA3140231A1 CA 3140231 A1 CA3140231 A1 CA 3140231A1 CA 3140231 A CA3140231 A CA 3140231A CA 3140231 A CA3140231 A CA 3140231A CA 3140231 A1 CA3140231 A1 CA 3140231A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pain
- formula
- substituted
- unsubstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne un composé propylamine hétéroaryle 3-aryloxyl-3 à cinq chaînons, une forme cristalline et une utilisation associée. Plus particulièrement, la présente invention concerne un composé, ou un sel pharmaceutiquement acceptable ou un promédicament de celui-ci, le composé ayant une structure de formule I. Le composé, ou un sel pharmaceutiquement acceptable ou un promédicament de celui-ci selon la présente invention a une excellente fonction d'inhibition pour une protéine de canal à potentiel de récepteur transitoire (TPR), et a une bonne fonction de traitement pour des maladies associées au TPR.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910411311 | 2019-05-16 | ||
| CN201910411311.X | 2019-05-16 | ||
| PCT/CN2019/100846 WO2020035040A1 (fr) | 2018-08-17 | 2019-08-15 | Composé propylamine hétéroaryle 3-aryloxyl-3 à cinq chaînons, et utilisation associée |
| CNPCT/CN2019/100846 | 2019-08-15 | ||
| CN202010093736.3A CN111943943A (zh) | 2019-05-16 | 2020-02-14 | 3-芳氧基-3-五元杂芳基-丙胺类化合物及其晶型和用途 |
| CN202010093736.3 | 2020-02-14 | ||
| PCT/CN2020/090354 WO2020228789A1 (fr) | 2019-05-16 | 2020-05-14 | Composé propylamine hétéroaryle 3-aryloxyl-3 à cinq chaînons, forme cristalline et utilisation associée |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3140231A1 true CA3140231A1 (fr) | 2020-11-19 |
| CA3140231C CA3140231C (fr) | 2024-06-04 |
Family
ID=73336943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3140231A Active CA3140231C (fr) | 2019-05-16 | 2020-05-14 | Compose propylamine heteroaryle 3-aryloxyl-3 a cinq chainons, forme cristalline et utilisation associee |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN111943943A (fr) |
| CA (1) | CA3140231C (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12139476B2 (en) | 2018-08-17 | 2024-11-12 | Shanghai Leado Pharmatech Co. Ltd. | 3-aryloxyl-3-five-membered heteroaryl propylamine compound and use thereof |
| WO2020228789A1 (fr) | 2019-05-16 | 2020-11-19 | 上海璃道医药科技有限公司 | Composé propylamine hétéroaryle 3-aryloxyl-3 à cinq chaînons, forme cristalline et utilisation associée |
| CN112794860B (zh) * | 2021-03-24 | 2021-06-29 | 上海肇钰医药科技有限公司 | 噁唑嘧啶酮酰胺类化合物或其可药用盐，制备方法及用途 |
| CN115703767A (zh) * | 2021-08-12 | 2023-02-17 | 上海璃道医药科技有限公司 | 3-芳氧基-3-五元杂芳基-丙胺类化合物的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0112122D0 (en) * | 2001-05-18 | 2001-07-11 | Lilly Co Eli | Heteroaryloxy 3-substituted propanamines |
| CN107840845B (zh) * | 2016-09-19 | 2024-07-02 | 上海璃道医药科技有限公司 | 胺类化合物的新用途 |
| EP3339307A1 (fr) * | 2016-12-20 | 2018-06-27 | Laboratorios del Dr. Esteve, S.A. | Dérivés bicycliques contenant de l'azote destinés à traiter la douleur et des états liés à la douleur |
| JP7283669B2 (ja) * | 2018-08-17 | 2023-05-30 | チャンチョウ ピエン ツェ フアン ファーマシューティカル カンパニー リミテッド | ３－アリールオキシ－３－アリール－プロピルアミン化合物およびその用途 |
| US12139476B2 (en) * | 2018-08-17 | 2024-11-12 | Shanghai Leado Pharmatech Co. Ltd. | 3-aryloxyl-3-five-membered heteroaryl propylamine compound and use thereof |
-
2020
- 2020-02-14 CN CN202010093736.3A patent/CN111943943A/zh active Pending
- 2020-05-14 CA CA3140231A patent/CA3140231C/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3140231C (fr) | 2024-06-04 |
| CN111943943A (zh) | 2020-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7272709B2 (ja) | ３－アリールオキシル－３－５員ヘテロアリール－プロピルアミン化合物およびその使用 | |
| CA3140231C (fr) | Compose propylamine heteroaryle 3-aryloxyl-3 a cinq chainons, forme cristalline et utilisation associee | |
| AU2020276005B2 (en) | 3-aryloxyl-3-five-membered heteroaryl propylamine compound, and crystal form and use thereof | |
| EP3838900B1 (fr) | Composés de 3-aryloxy-3-aryl-propylamine et utilisations associées | |
| JPWO2002100819A1 (ja) | Ｎ−アリールフェニルアセトアミド誘導体及びそれを含有する医薬組成物 | |
| CN114181170B (zh) | 一种10h-吩噻嗪类铁死亡抑制剂及其制备方法与应用 | |
| JP7264999B2 (ja) | ２－（１－アシルオキシ－ｎ－ペンチル）安息香酸と塩基性アミノ酸またはアミノグアニジンによって形成される塩と、その製造方法及び用途 | |
| CN106478502B (zh) | 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用 | |
| JP7446591B2 (ja) | ３－アリールオキシ－３－５員ヘテロアリール－プロピルアミン化合物の調製方法および結晶形 | |
| JP2021505573A (ja) | ベータ−２選択的アドレナリン性受容体アゴニスト | |
| CN114149386A (zh) | 芳基戊二烯酰胺类醛脱氢酶抑制剂、其合成方法及用途 | |
| CN101195597A (zh) | 1-取代-4,4-二取代氨基硫脲类化合物、其制备方法以及其用途 | |
| CN120097888B (zh) | 二氢吲哚芳酸醚类衍生物及其制备方法与用途 | |
| KR20250045262A (ko) | 신규 페닐프로파노이드 유도체 화합물을 유효성분으로 포함하는 교모세포종의 예방 또는 치료용 조성물 | |
| CN119118863A (zh) | 9-菲酰胺类衍生物及其制备方法与用途 | |
| CN120136683A (zh) | 儿茶酚醚类化合物及其药物组合物和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20211112 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250505 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250505 |